Received May 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U7829AA | — |
HBP states improperly stored GARDASIL 9, PEDVAX HIB, ROTATEQ, VAXELIS pfs, MMR II, PROQUAD, VARIVAX and VAXNEUVANCE may have been administered to patients between 2/3/2026 through 4/1/2026.; no adverse event; This non-serious spontaneous Safety Report was received with reference number: 02973462 (Interation number: 02973444) by Partner on 01-APR-2026 and forwarded on 02-APR-2026. ADDITIONAL NON-SIGNIFICANT FOLLOW-UP INFORMATION was received by Partner on 02-APR-2026 and forwarded on 03-APR-2026. ADDITIONAL NON-SIGNIFICANT FOLLOW-UP INFORMATION was received by Partner on 03-APR-2026 and forwarded on 06-APR-2026 from a consumer professional. Due to the nature of the event the causal relationship between the event of HBP states improperly stored GARDASIL 9, PEDVAX HIB, ROTATEQ, VAXELIS pfs, MMR II, PROQUAD, VARIVAX and VAXNEUVANCE may have been administered to patients between 2/3/2026 through 4/1/2026' and Vaxelis is not applicable. Further information expected. Significant follow-up information was received from health care professional on 24-APR-2026 and forwarded on 24-APR-2026. The case is maintained as non-serious, but became valid as patient identifiers were provided. Due to the nature of the event the causal relationship between the event of HBP states improperly stored GARDASIL 9, PEDVAX HIB, ROTATEQ, VAXELIS pfs, MMR II, PROQUAD, VARIVAX and VAXNEUVANCE may have been administered to patients between 2/3/2026 through 4/1/2026' and Vaxelis is not applicable. Further information is not expected. SIGNIFICANT FOLLOW-UP INFORMATION from health care professional on 24-APR-2026. ADDITIONAL NON-SIGNIFICANT DUPLICATE INFORMATION was received by Partner 25-APR-2026 and forwarded on 25-APR-2026 from a Health professional. Due to the nature of the event the causal relationship between the events of HBP states improperly stored GARDASIL 9, PEDVAX HIB, ROTATEQ, VAXELIS pfs, MMR II, PROQUAD, VARIVAX and VAXNEUVANCE may have been administered to patients between 2/3/2026 through 4/1/2026 and No adverse event' and Vaxelis is not applicable. No further information expected.
Prophylaxis